| pubmed-article:10070020 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C0017725 | lld:lifeskim |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C1623038 | lld:lifeskim |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C0017715 | lld:lifeskim |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C0815327 | lld:lifeskim |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C0596624 | lld:lifeskim |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:10070020 | lifeskim:mentions | umls-concept:C1880177 | lld:lifeskim |
| pubmed-article:10070020 | pubmed:issue | 3 Pt 1 | lld:pubmed |
| pubmed-article:10070020 | pubmed:dateCreated | 1999-4-15 | lld:pubmed |
| pubmed-article:10070020 | pubmed:abstractText | Net hepatic glycogenolysis and gluconeogenesis were examined in normal (n = 4) and cirrhotic (n = 8) subjects using two independent methods [13C nuclear magnetic resonance spectroscopy (NMR) and a 2H2O method]. Rates of net hepatic glycogenolysis were calculated by the change in hepatic glycogen content before ( approximately 11:00 PM) and after ( approximately 7:00 AM) an overnight fast using 13C NMR and magnetic resonance imaging. Gluconeogenesis was calculated as the difference between the rates of glucose production determined with an infusion of [6,6-2H2]glucose and net hepatic glycogenolysis. In addition, the contribution of gluconeogenesis to glucose production was determined by the 2H enrichment in C-5/C-2 of blood glucose after intake of 2H2O (5 ml/kg body water). Plasma levels of total and free insulin-like growth factor I (IGF-I) and IGF-I binding proteins-1 and -3 were significantly decreased in the cirrhotic subjects (P < 0.01 vs. controls). Postprandial hepatic glycogen concentrations were 34% lower in the cirrhotic subjects (P = 0.007). Rates of glucose production were similar between the cirrhotic and healthy subjects [9.0 +/- 0.9 and 10.0 +/- 0.8 micromol. kg body wt-1. min-1, respectively]. Net hepatic glycogenolysis was 3.5-fold lower in the cirrhotic subjects (P = 0.01) and accounted for only 13 +/- 6% of glucose production compared with 40 +/- 10% (P = 0.03) in the control subjects. Gluconeogenesis was markedly increased in the cirrhotic subjects and accounted for 87 +/- 6% of glucose production vs. controls: 60 +/- 10% (P = 0.03). Gluconeogenesis in the cirrhotic subjects, as determined from the 2H enrichment in glucose C-5/C-2, was also increased and accounted for 68 +/- 3% of glucose production compared with 54 +/- 2% (P = 0.02) in the control subjects. In conclusion, cirrhotic subjects have increased rates of gluconeogenesis and decreased rates of net hepatic glycogenolysis compared with control subjects. These alterations are likely important contributing factors to their altered carbohydrate metabolism. | lld:pubmed |
| pubmed-article:10070020 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10070020 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10070020 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10070020 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10070020 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10070020 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10070020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10070020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10070020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10070020 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10070020 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10070020 | pubmed:issn | 0002-9513 | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:LandauB RBR | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:SchumannW CWC | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:PetersenK FKF | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:NavarroVV | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:ChandramouliV... | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:ShulmanG IGI | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:KrssakMM | lld:pubmed |
| pubmed-article:10070020 | pubmed:author | pubmed-author:HundalRR | lld:pubmed |
| pubmed-article:10070020 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10070020 | pubmed:volume | 276 | lld:pubmed |
| pubmed-article:10070020 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10070020 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10070020 | pubmed:pagination | E529-35 | lld:pubmed |
| pubmed-article:10070020 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:meshHeading | pubmed-meshheading:10070020... | lld:pubmed |
| pubmed-article:10070020 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10070020 | pubmed:articleTitle | Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. | lld:pubmed |
| pubmed-article:10070020 | pubmed:affiliation | Department of Internal Medicine, Yale University School of Medicine, New Haven, Conneticut 06520-8020, USA. Kitt.Petersen@Yale.edu | lld:pubmed |
| pubmed-article:10070020 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10070020 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10070020 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10070020 | lld:pubmed |
